ADM launches supportive solutions platform to meet growing demand for personalised nutrition

ADM has unveiled a supportive solutions platform for users of GLP-1 and other anti-obesity medications (AOMs).

Backed by proprietary consumer insights, along with scientific and market analysis, ADM’s solutions platform leverages the company’s extensive ingredient pantry and full-formula product development capabilities. These leading capabilities will help its customers address the emerging demand for tailored nutrition support for consumers currently engaging with AOMs, as well as those discontinuing the medications.

According to ADM’s proprietary research, 83% of US consumers taking AOMs find food products to be appealing when they are specifically marketed as supportive of people on GLP-1 medications (ADM Outside Voice, Anti-Obesity Medications Survey, September 2024.

“The use of GLP-1 treatments continues to rapidly increase, creating an incredibly dynamic market with a new segment of consumers with unique needs,” said Ian Pinner, senior vice president, president, nutrition, and chief sales and marketing officer, ADM. “Food, beverage and dietary supplement manufacturers can support consumers with tailored solutions that address their needs at every stage of their weight management journey.”

Survey respondents – adult consumers in the US currently taking AOMs – report factors like nutrition (64%), taste (64%) and portion size (60%) have become more important when purchasing foods and beverages. Additionally, 74% are more open to trying new foods and 83% are cooking more at home. Since starting GLP-1 treatments, many of these consumers have intentionally increased their intake of plant-based protein (41%), fibre (49%) and probiotics or prebiotics (39% – ADM Outside Voice, Anti-Obesity Medications Survey, September 2024).

The ADM solutions platform includes the introduction of over 25 market-ready GLP-1 complementary food and supplement concepts containing a multitude of functional ingredients to target specific needs of AOM users. The concepts are formulated with functional, clean-tasting plant-based and wholesome ingredients, science-backed prebiotic fibre, probiotics, postbiotics, botanical extracts, sweetening solutions, resistant tapioca starch, a digestive-support flour blend and a keto-friendly/carb-conscious flour replacer, and naturally derived flavours and colours.

“Our tested and ready-to-market concepts tap into our unparalleled pantry and our full-formulation expertise to accelerate food and beverage manufacturers’ speed to market and help them differentiate with elevated format, flavour, texture and functionality,” said Pinner. “Through our platform, we’re addressing the changing taste preferences that may come with engaging with GLP-1 medications, such as the altered perception of sweetness. We are also delivering highly sought-after nutrient density in smaller servings and providing alternative solutions to support reducing persistent thoughts about food, commonly known as ‘food noise,’ if medication use is reduced.”

Related content